CN116261569A - 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用 - Google Patents

用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用 Download PDF

Info

Publication number
CN116261569A
CN116261569A CN202180065892.1A CN202180065892A CN116261569A CN 116261569 A CN116261569 A CN 116261569A CN 202180065892 A CN202180065892 A CN 202180065892A CN 116261569 A CN116261569 A CN 116261569A
Authority
CN
China
Prior art keywords
dose
day
once
weeks
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180065892.1A
Other languages
English (en)
Chinese (zh)
Inventor
内德·纳贾菲亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CN116261569A publication Critical patent/CN116261569A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180065892.1A 2020-09-21 2021-09-16 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用 Pending CN116261569A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081182P 2020-09-21 2020-09-21
US63/081,182 2020-09-21
PCT/US2021/050590 WO2022060931A1 (en) 2020-09-21 2021-09-16 Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)

Publications (1)

Publication Number Publication Date
CN116261569A true CN116261569A (zh) 2023-06-13

Family

ID=78087569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180065892.1A Pending CN116261569A (zh) 2020-09-21 2021-09-16 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用

Country Status (10)

Country Link
US (1) US20230348579A1 (https=)
EP (1) EP4213940A1 (https=)
JP (1) JP2023542521A (https=)
KR (1) KR20230073261A (https=)
CN (1) CN116261569A (https=)
AU (1) AU2021344411A1 (https=)
CA (1) CA3173003A1 (https=)
IL (1) IL301350A (https=)
MX (1) MX2023003256A (https=)
WO (1) WO2022060931A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025166118A1 (en) 2024-02-02 2025-08-07 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer

Also Published As

Publication number Publication date
JP2023542521A (ja) 2023-10-10
EP4213940A1 (en) 2023-07-26
AU2021344411A9 (en) 2024-09-26
IL301350A (en) 2023-05-01
AU2021344411A1 (en) 2023-04-27
KR20230073261A (ko) 2023-05-25
MX2023003256A (es) 2023-04-11
WO2022060931A1 (en) 2022-03-24
US20230348579A1 (en) 2023-11-02
CA3173003A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
JP6673840B2 (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
AU2024266818B2 (en) Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS)
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP2023101717A (ja) 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与
TW201945396A (zh) 最佳化抗-tl1a抗體
JP2023134701A (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2026026191A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
TW202539734A (zh) 使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法
CN116261569A (zh) 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用
RU2822664C2 (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
JP6893265B2 (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
JP2024521474A (ja) 皮膚筋炎（ｄｍ）を治療するための抗ｃ５抗体の投与量及び投与
CN121127494A (zh) 用于治疗自身免疫性疾病的抗cd38抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination